Table 2.
Thromboembolic Events and Antithrombotic Treatment of Patients, Overall and by Sex
| Variable | All patients | Men | Women | P value |
|---|---|---|---|---|
| (n=21 528) | (n=11 644) | (n=9884) | ||
| Venous thromboembolic events | ||||
| DVT (+/−PE) | 508 (2.4) | 317 (2.7) | 191 (1.9) | <0.001 |
| PE (+/−DVT) | 385 (1.8) | 223 (1.9) | 162 (1.6) | 0.141 |
| Arterial thromboembolic events | ||||
| Acute limb ischemia | 44 (0.2) | 29 (0.2) | 15 (0.2) | 0.155 |
| Myocardial infarction | 655 (3.0) | 377 (3.2) | 278 (2.8) | 0.077 |
| Ischemic stroke | 168 (0.8) | 106 (0.9) | 62 (0.6) | 0.023 |
| Left ventricular thrombus | 168 (0.8) | 106 (0.9) | 62 (0.6) | 0.023 |
| Bleeding requiring transfusion | 747 (3.5) | 436 (3.7) | 311 (3.1) | 0.018 |
| Required ICU care | 6604 (30.7) | 4008 (34.4) | 2596 (26.3) | <0.001 |
| Missing, n | 101 | 56 | 45 | |
| Severe COVID‐19 | 4347 (20.3) | 2699 (23.3) | 1648 (16.7) | <0.001 |
| Missing, n | 104 | 56 | 48 | |
| Hospital length of stay, days | ||||
| Mean (SD) | 10.0 (11.4) | 10.7 (12.4) | 9.0 (10.2) | <0.001 |
| Median (IQR) | 6.5 (3.6–11.7) | 6.7 (3.7–12.6) | 5.8 (3.5–10.8) | <0.001 |
| Death | 3326 (15.4) | 2021 (17.4) | 1305 (13.2) | <0.001 |
| Prehospital antithrombotics | ||||
| Antiplatelet | 5819 (27.1) | 3285 (28.3) | 2534 (25.7) | <0.001 |
| Missing, n | 70 | 39 | 31 | |
| Aspirin | 5327 (24.8) | 3001 (25.9) | 2326 (23.6) | 0.611 |
| P2y12 inhibitor | 968 (4.5) | 577 (5.0) | 391 (4.0) | 0.033 |
| Other antiplatelet | 150 (0.7) | 90 (0.8) | 60 (0.6) | 0.420 |
| Dual antiplatelet | 621 (2.9) | 382 (3.3) | 239 (2.4) | 0.008 |
| Anticoagulant | 2964 (14.1) | 1677 (14.7) | 1287 (13.3) | 0.005 |
| Missing, n | 442 | 221 | 221 | |
| Direct thrombin inhibitor | 109 (0.5) | 58 (0.5) | 51 (0.5) | 0.526 |
| Factor Xa inhibitor | 1429 (0.7) | 779 (0.7) | 650 (0.7) | 0.028 |
| Warfarin | 519 (2.5) | 297 (2.6) | 222 (2.3) | 0.797 |
| Other anticoagulant | 937 (4.4) | 561 (4.9) | 376 (3.9) | 0.017 |
| In‐hospital anticoagulants | ||||
| Prophylactic dose anticoagulant | ||||
| Subcutaneous heparin | 3468 (25.0) | 1966 (26.6) | 1502 (23.3) | <0.001 |
| Missing, n | 7681 | 4254 | 3427 | |
| LMWH, low dose | 6547 (47.4) | 3460 (46.9) | 3087 (47.8) | 0.307 |
| Missing, n | 7706 | 4275 | 3431 | |
| Therapeutic dose anticoagulant | ||||
| Intravenous heparin | 1381 (10.0) | 877 (11.9) | 504 (7.8) | <0.001 |
| Missing, n | 7695 | 4268 | 3427 | |
| LMWH, intermediate dose | 1717 (12.4) | 913 (12.4) | 804 (12.4) | 0.909 |
| Missing, n | 7679 | 4258 | 3421 | |
| LMWH, full dose | 1623 (11.7) | 994 (13.5) | 629 (9.7) | <0.001 |
| Missing, n | 7673 | 4256 | 3417 | |
| Argatroban | 78 (0.6) | 51 (0.7) | 27 (0.4) | 0.041 |
| Missing, n | 7493 | 4173 | 3320 | |
| Bivalirudin | 26 (0.2) | 17 (0.2) | 9 (0.1) | 0.295 |
| Missing, n | 7493 | 4173 | 3320 | |
| DOAC | 1460 (10.4) | 863 (11.5) | 597 (9.1) | <0.001 |
| Missing, n | 7500 | 4173 | 3327 | |
| Apixaban | 1108 (7.9) | 658 (8.8) | 450 (6.8) | <0.001 |
| Dabigatran | 22 (0.1) | 17 (0.2) | 5 (<0.1) | 0.041 |
| Edoxaban | 1 (<0.1) | 1 (<0.1) | 0 | … |
| Rivaroxaban | 319 (2.3) | 182 (2.4) | 137 (2.1) | 0.188 |
| Warfarin | 330 (2.4) | 198 (2.7) | 132 (2.0) | 0.015 |
| Missing, n | 7510 | 4181 | 3329 | |
Data are given as number (percentage), unless otherwise indicated. Percentages are calculated out of the number of nonmissing values for that variable. The number of missing values for each variable is noted in the table where necessary. Sex is defined as determined by the registry. Severe COVID‐19 is defined as the need for invasive mechanical ventilation, extracorporeal circulatory or pulmonary support, or vasopressor or inotropes. DOAC indicates direct oral anticoagulant; DVT, deep vein thrombosis; ICU, intensive care unit; IQR, interquartile range; LMWH, low‐molecular‐weight heparin; and PE, pulmonary embolism.